Identification of Hemochromatosis Gene Polymorphisms in Chronically Transfused Patients with Sickle Cell Diseases

American Journal of Hematology

Volumn 74, Issue 4, 2003, Pages 243-248

  Jeng, Michael R ^a   Adams Graves, Patricia ^b   Howard, Thad A ^c   Whorton, Matthew R ^c   Li, Chin Shang ^d   Ware, Russell E ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Hemochromatosis; Iron overload; Sickle cell disease

Indexed keywords

DNA; FERRITIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; DNA DETERMINATION; DNA POLYMORPHISM; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; GENE FREQUENCY; GENE MUTATION; GENETIC SCREENING; HEMOCHROMATOSIS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INFANT; IRON OVERLOAD; MALE; MUTATIONAL ANALYSIS; NEGRO; POPULATION GENETICS; PREVALENCE; PRIORITY JOURNAL; SICKLE CELL ANEMIA;

ADOLESCENT; ADULT; AFRICAN AMERICANS; ANEMIA, SICKLE CELL; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENOTYPE; HEMOCHROMATOSIS; HUMANS; IRON OVERLOAD; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PREVALENCE;

EID: 0345306730     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10426     Document Type: Article

References (39)

1. Lebron JA, Bennett MJ, Vaughn DE, et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 1998;93(1):111-123.
2. Waheed AS, Parkkila J, Saarnio RE, et al. Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum. Proc Natl Acad Sci U S A 1999;96(4):1579-1584.
3. McLaren CE, Gordeuk VR, Looker AC, et al. Prevalence of heterozygotes for hemochromatosis in the white population of the United States. Blood 1995;86(5):2621-2627.
4. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP.Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988;318(21): 1355-1362.
5. Simon MM, Bourel B, Fauchet R. Idiopathic hemochromatosis. Demonstration of recessive transmission and early detection by family HLA typing. N Engl J Med 1977;297(19):1017-1021.
6. Edwards CQ, Skolnick MH, Kushner JP. Hereditary hemochromatosis: contributions of genetic analyses. Prog Hematol 1981;12: 43-71.
7. Koeken AC, Cobbaert W, van Quint DL. Genotyping of hemochromatosis-associated mutations in the HFE gene by PCR-RFLP and a novel reverse hybridization method. Clin Chem Lab Med 2002;40(2):122-125.
8. Trent RJ, Le H, Yu B, Young G, Bowden DK. DNA testing for haemochromatosis: diagnostic, predictive and screening implications. Pathology 2000;32(4):274-279.
9. Barton JC, Acton RT. Inheritance of two HFE mutations in African Americans: cases with hemochromatosis phenotypes and estimates of hemochromatosis phenotype frequency. Genet Med 2001;3(4):294-300.
10. Monaghan KG, Rybicki BA, Shurafa M, Feldman GL. Mutation analysis of the HFE gene associated with hereditary hemochromatosis in African Americans. Am J Hematol 1998;58(3):213-217.
11. Marshall DS, Linfert DR, Tsongalis GJ. Prevalence of the C282Y and H63D polymorphisms in a multi-ethnic control population. Int J Mol Med 1999;4(4):389-393.
12. Mohler DN, Wheby MS. Hemochromatosis heterozygotes may have significant iron overload when they also have hereditary spherocytosis. Am J Med Sci 1986;292(5):320-324.
13. Fargion S, Cappellini MD, Piperno A, Panajotopoulos N, Ronchi G, Fiorelli G. Association of hereditary spherocytosis and idiopathic hemochromatosis. A synergistic effect in determining iron overload. Am J Clin Pathol 1986;86(5):645-649.
14. Sampietro MA, Piperno L, Lupica C, et al. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology 1998;27(1):181-184.
15. Edwards CQ, Skolnick MH, Kushner JP. Coincidental nontransfusional iron overload and thalassemia minor: association with HLA-linked hemochromatosis. Blood 1981;58(4):844-848.
16. Aguilar-Martinez P, Schved JF, Badens C, et al. Iron overload in thalassaemias and genetic haemochromatosis. Eur J Haematol 2000;64(4):279-280.
17. Piperno AR, Mariani C, Arosio A, et al. Haemochromatosis in patients with beta-thalassaemia trait. Br J Haematol 2000;111(3): 908-914.
18. Melis MA, Cau M, Deidda F, Barella S, Cao A, Galanello R. H63D mutation in the HFE gene increases iron overload in beta-thalassemia carriers. Haematologica 2002;87(3):242-245.
19. Arruda VR, Agostinho MF, Cancado R, Costa FF, Saad ST. Beta-thalassemia trait might increase the severity of hemochromatosis in subjects with the C282Y mutation in the HFE gene. Am J Hematol 2000;63(4):230.
20. Borgna-Pignatti C, Solinas A, Bombieri C, et al. The haemochromatosis mutations do not modify the clinical picture of thalassaemia major in patients regularly transfused and chelated. Br J Haematol 1998;103(3):813-816.
21. Longo F, Zecchina G, Sbaiz L, Fischer R, Piga A, Camaschella C. The influence of hemochromatosis mutations on iron overload of thalassemia major. Haematologica 1999;84(9):799-803.
22. Conrad ME. Sickle cell disease and hemochromatosis. Am J Hematol 1991;38(2):150-152.
23. Pootrakul PK, Kitcharoen P, Yansukon P, et al. The effect of erythroid hyperplasia on iron balance. Blood 1988;71(4):1124-1129.
24. Fargion S, Sampietro M, Cappellini MD. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. In: Barton JC, Edwards CQ, editors. Thalassemias and their interaction with hemochromatosis. United Kingdom: Cambridge University Press; 2002. p 435-441.
25. Camaschella CA, Roetto P, Gasparini A, et al. Allelic association of microsatellites of 6p in Italian hemochromatosis patients. Hum Genet 1996;97(4):476-481.
26. Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001;38(1 Suppl 1):30-36.
27. Rees DC, Luo LY, Thein SL, Singh BM, Wickramasinghe S. Nontransfusional iron overload in thalassemia: association with hereditary hemochromatosis. Blood 1997;90(8):3234-3236.
28. Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr 2001;139(6):785-789.
29. Adams RJ. Stroke prevention in sickle cell disease. Curr Opin Hematol 2000;7(2):101-105.
30. Adams RJ. Stroke prevention and treatment in sickle cell disease. Arch Neurol 2001;58(4):565-568.
31. Harmatz PE, Butensky K, Quirolo R, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000;96(1):76-79.
32. Files BD, Brambilla A, Kutlar S, et al. Longitudinal changes in ferritin during chronic transfusion: a report from the Stroke Prevention Trial in Sickle Cell Anemia (STOP). J Pediatr Hematol Oncol 2002;24(4):284-290.
33. Angelucci ED, Baronciani G, Lucarelli M, et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol 1995;89(4): 757-761.
34. Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993;42(1):81-85.
35. Beutler ET, Gelbart T, Lee P. Haptoglobin polymorphism and iron homeostasis. Clin Chem 2002;48(12):2232-2235.
36. Beutler E, Griffin MJ, Gelbart T, West C. A previously undescribed nonsense mutation of the HFE gene. Clin Genet 2002; 61(1):40-42.
37. Beutler E, West C. Polymorphisms in the 5′ flanking region of the HFE gene: linkage disequilibrium and relationship to iron homeostasis. Blood Cells Mol Dis 2002;28(2):191-195.
38. Wurapa RK, Gordeuk VR, Brittenham GM, Khiyami A, Schechter GP, Edwards CQ. Primary iron overload in African Americans. Am J Med 1996;101(1):9-18.
39. Lee PL, Gelbart T, West C, Halloran C, Felitti V, Beutler E. A study of genes that may modulate the expression of hereditary hemochromatosis: transferrin receptor-1, ferroportin, ceruloplasmin, ferritin light and heavy chains, iron regulatory proteins (IRP)-1 and -2, and hepcidin. Blood Cells Mol Dis 2001;27(5):783-802.